Skip links

Glaucoma GPX-501


Freya has developed and demonstrated GPX-501 - Bimatoprost eluting contact lenses to provide sustained release resulting in therapeutic concentrations for extended durations, eliminating the peaks and troughs in concentrations from drops, which may cause sub-therapeutic concentration between drop instillations, which can lead to infection proliferation and/or development of resistance


Vitamin E technology is a Platform Technology Adaptable to any drug of interest for delivery to front and back of eye

Bimatoprost release (µg)

Weeklong glaucoma therapy to eliminate lack of compliance